High Net Worth Advisory Group’s AbbVie ABBV Stock Holding History

High Net Worth Advisory Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.4M	Sell	45,390 -51	-0.1%	-$11K	2.43%	8
2026 Q1	$9.88M	Sell	45,441 -60	-0.1%	-$13.3K	2.31%	8
2025 Q4	$10.4M	Sell	45,501 -17	-0%	-$3.87K	2.4%	8
2025 Q3	$10.5M	Sell	45,518 -454	-1%	-$92.5K	2.54%	7
2025 Q2	$8.53M	Sell	45,972 -40	-0.1%	-$7.43K	2.26%	8
2025 Q1	$9.64M	Buy	46,012 +1	+0%	+$194	2.72%	8
2024 Q4	$8.18M	Sell	46,011 -563	-1%	-$104K	2.28%	8
2024 Q3	$9.2M	Hold	46,574	–	–	2.52%	8
2024 Q2	$7.99M	Buy	46,574 +1	+0%	+$166	2.42%	8
2024 Q1	$8.48M	Buy	46,573 +2,600	+6%	+$448K	2.67%	8
2023 Q4	$6.81M	Buy	43,973 +41	+0.1%	+$5.98K	2.53%	7
2023 Q3	$6.55M	Sell	43,932 -135	-0.3%	-$19.8K	2.62%	7
2023 Q2	$5.94M	Sell	44,067 -89	-0.2%	-$13.1K	2.3%	8
2023 Q1	$7.04M	Sell	44,156 -47	-0.1%	-$7.19K	2.87%	7
2022 Q4	$7.14M	Buy	44,203 +65	+0.1%	+$9.97K	2.78%	7
2022 Q3	$5.92M	Hold	44,138	–	–	2.53%	7
2022 Q2	$6.76M	Sell	44,138 -293	-0.7%	-$44.8K	2.81%	6
2022 Q1	$7.2M	Hold	44,431	–	–	2.62%	7
2021 Q4	$6.02M	Buy	+44,431	New	+$5.25M	2.1%	8

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

High Net Worth Advisory Group's ABBV Position: Q2 2026 in Review

High Net Worth Advisory Group reduced its AbbVie (ABBV) stake by 0.11% in Q2 2026, selling an estimated $11K and leaving 45,390 shares worth $11.4M. The position accounts for 2.43% of the portfolio, ranked #8.

High Net Worth Advisory Group first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

High Net Worth Advisory Group held 45,390 shares of AbbVie worth $11.4M as of Q2 2026.
High Net Worth Advisory Group sold 51 AbbVie shares in Q2 2026, an estimated $11K.
AbbVie made up 2.43% of High Net Worth Advisory Group's portfolio in Q2 2026, its #8 holding.
High Net Worth Advisory Group first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on High Net Worth Advisory Group's 13F filing for Q2 2026, filed 29 Jul 2026.